Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

Inclusion Criteria: * Age 19 to 45 years * BMI score 19 kg/m2 to 28 kg/m2 * SBP \< 140 mmHg and ≤ 90 mmHg or DBP \< 90 mmHg and ≥ 50 mmHg * Eligible according to the laboratory results of hematology, blood chemistry and urinalysis * Voluntarily signed the informed consent form Exclusion Criteria: * Gastrointestinal diseases or surgery which may affect absorption of the investigational products within 6 months * History of hypersensitivity * history of Cardiovascular disease * History of degenerative Retina disease * Lactose intolerance * Medical history of vision loss * Clinically significant disorders of allergy, drug hypersensitivity reaction, hepatobiliary system, kidney, neurology, respiratory, hemato-oncology, endocrine, dermatology, urology, ophthalmology, psychiatry, musculo-skeletal system, immunology, otorhinolaryngology, and cardiovascular system * Donated whole blood (transfusion, apheresis etc..) within 60 days * Participated and administered the investigational products in other clinical trial within 90 days * Taking drugs which may affect Clinical trial within 30 days * Smoked more than 10 cigarettes a day for past 30 days * Excessive alcohol consumption (\> 3 units/week, 1 unit) * Taking food which may affect Clinical trial within 7 days * Positive result from Urinary test * Positive result from Serum test * Clinically significant disorders result from Electrocardiography test * Not eligible due to investigator's judgments